EE639 Cost-per-Responder Analysis of Bimekizumab Against Licensed Anti-Interleukin-17A Therapies in Axial Spondyloarthritis From a UK Perspective Focusing on BASDAI50 Treatment Response
Abstract
Authors
N Bithal T Rehman C McCabe F Obam N Lyris D Willems